<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634191</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-CP-024</org_study_id>
    <secondary_id>20200149</secondary_id>
    <nct_id>NCT01634191</nct_id>
  </id_info>
  <brief_title>Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Effects of Age and Sex on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effects of age and sex on the pharmacokinetics&#xD;
      and safety of a single oral dose of 30 mg apremilast in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, parallel group study where eligible elderly adults (aged 65-85 years&#xD;
      inclusive) and younger adults (aged 18-55 years inclusive) and who are matched to the elderly&#xD;
      participants by sex and body mass index (BMI) (± 10%) will receive a single dose of 30 mg&#xD;
      apremilast under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Actual">April 1, 2012</completion_date>
  <primary_completion_date type="Actual">March 1, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
    <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.&#xD;
AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
    <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.&#xD;
AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
    <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
    <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Apremilast</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
    <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration of Apremilast by Sex</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
    <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
    <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
    <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From first dose of study drug up to 11 days</time_frame>
    <description>An adverse event (AE) was any noxious, unintended, or untoward medical occurrence that appeared or worsened in a participant during the course of the study. It could have been a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing condition) was considered an AE.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Elderly: Apremilast 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Younger: Apremilast 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>One oral 30 mg dose of apremilast</description>
    <arm_group_label>Elderly: Apremilast 30 mg</arm_group_label>
    <arm_group_label>Younger: Apremilast 30 mg</arm_group_label>
    <other_name>CC-10004</other_name>
    <other_name>Otezla®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria for elderly group&#xD;
&#xD;
          1. Healthy male or female subjects of any ethnic origin between ages of 65 and 85&#xD;
             inclusive with a body mass index (BMI) between 18 and 35.&#xD;
&#xD;
          2. Females must have been surgically sterilized at least 6 months prior to screening or&#xD;
             be postmenopausal (to be confirmed by lab tests).&#xD;
&#xD;
          3. Males must agree to use latex or polyurethane condoms when engaging in sex during the&#xD;
             study and for at least 28 days after dosing.&#xD;
&#xD;
          4. Elderly subjects with stable, chronic medical condition may be eligible if the&#xD;
             condition is well-controlled and medications do not interfere with study procedures or&#xD;
             pharmacokinetic interpretation&#xD;
&#xD;
        Inclusion Criteria for younger group:&#xD;
&#xD;
          1. Healthy male or female of any ethnic origin between the ages of 18 and 55 inclusive&#xD;
             with a BMI between 18 and 35.&#xD;
&#xD;
          2. Males must agree to use latex or polyurethane condoms when engaging in sex during the&#xD;
             study and for at least 28 days after dosing.&#xD;
&#xD;
          3. Females who are able to become pregnant have a negative pregnancy test at screening&#xD;
             and baseline, and must agree to use one of the following:&#xD;
&#xD;
               -  a highly effective form of contraception (ex. Non-oral hormonal, intrauterine&#xD;
                  device) OR&#xD;
&#xD;
               -  oral hormonal contraceptive plus one additional form of barrier contraception OR&#xD;
&#xD;
               -  two forms of barrier contraception These must be effective by the time of&#xD;
                  screening. For younger females who are not able to become pregnant, the&#xD;
                  conditions for the elderly females will apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition, including the presence of laboratory abnormalities, or psychiatric&#xD;
             illness, that would prevent the subject from signing the Informed Consent form, places&#xD;
             the subject at unacceptable risk if he were to participate in the study, or confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
          2. Presence of any surgical or medical conditions possibly affecting drug absorption,&#xD;
             distribution, metabolism, and excretion, or plans to have elective or medical&#xD;
             procedures during the conduct of the trial.&#xD;
&#xD;
          3. Exposure to an investigational drug (new chemical entity) within 30 days prior to the&#xD;
             first dose administration or 5 half-lives of that investigational drug, if known&#xD;
             (whichever is longer).&#xD;
&#xD;
          4. Subjects with known serum hepatitis, is a known carrier of hepatitis B surface&#xD;
             antigen, hepatitis C antibody, or human immunodeficiency virus antibody.&#xD;
&#xD;
          5. Subjects who have used prescription systemic or topical medications within 30 days of&#xD;
             dosing, unless it is being used to treat a stable, chronic medical condition. This&#xD;
             includes medication that is an inhibitor or inducer of P-glycoprotein transporter and&#xD;
             CYP-3A4/5 used within 14 days of dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Development Services</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <results_first_submitted>March 22, 2021</results_first_submitted>
  <results_first_submitted_qc>March 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2021</results_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apremilast</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>safety</keyword>
  <keyword>Pharmacokinetics and safety in healthy volunteer subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at two clinical research sites in the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Young: Apremilast 30 mg</title>
          <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Elderly: Apremilast 30 mg</title>
          <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Young Males</title>
          <description>Men aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Young Females</title>
          <description>Women aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Elderly Males</title>
          <description>Men aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Elderly Females</title>
          <description>Women aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="7.48"/>
                    <measurement group_id="B2" value="35.2" spread="7.19"/>
                    <measurement group_id="B3" value="70.4" spread="3.62"/>
                    <measurement group_id="B4" value="70.6" spread="4.72"/>
                    <measurement group_id="B5" value="52.4" spread="19.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="2.43"/>
                    <measurement group_id="B2" value="27.5" spread="2.59"/>
                    <measurement group_id="B3" value="26.3" spread="2.69"/>
                    <measurement group_id="B4" value="27.1" spread="2.42"/>
                    <measurement group_id="B5" value="26.9" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast</title>
        <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.&#xD;
AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.</description>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The pharmacokinetic (PK) population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Young: Apremilast</title>
            <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Elderly: Apremilast</title>
            <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast</title>
          <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.&#xD;
AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.</description>
          <population>The pharmacokinetic (PK) population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2832" spread="28.1"/>
                    <measurement group_id="O2" value="3235" spread="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the effect of age on the PK of apremilast after a single 30 mg dose, a 2-way analysis of variance (ANOVA) model was performed on the log-transformed AUC0-t. The ANOVA model included age group (elderly and young), sex (male and female), and age group by sex as a fixed effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>113</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.2</ci_lower_limit>
            <ci_upper_limit>135</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Elderly/Young) and 90% confidence interval (CI) of the ratio calculated from a 2-way ANOVA model, and presented as percentages.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>An adverse event (AE) was any noxious, unintended, or untoward medical occurrence that appeared or worsened in a participant during the course of the study. It could have been a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing condition) was considered an AE.</description>
        <time_frame>From first dose of study drug up to 11 days</time_frame>
        <population>Participants who received apremilast</population>
        <group_list>
          <group group_id="O1">
            <title>Young Males</title>
            <description>Men aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Young Females</title>
            <description>Women aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Elderly Males</title>
            <description>Men aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Elderly Females</title>
            <description>Women aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>An adverse event (AE) was any noxious, unintended, or untoward medical occurrence that appeared or worsened in a participant during the course of the study. It could have been a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing condition) was considered an AE.</description>
          <population>Participants who received apremilast</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to adverse event related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex</title>
        <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.&#xD;
AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.</description>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Males (Combined)</title>
            <description>Male participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Females (Combined)</title>
            <description>Female participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex</title>
          <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.&#xD;
AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.</description>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2634" spread="24.5"/>
                    <measurement group_id="O2" value="3382" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the effect of sex on the PK of apremilast after a single 30 mg dose, a 2-way analysis of variance (ANOVA) model was performed on the log-transformed AUC0-t. The ANOVA model included age group (elderly and young), sex (male and female), and age group by sex as a fixed effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>128</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>107</ci_lower_limit>
            <ci_upper_limit>154</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Female/Male) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast</title>
        <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Young: Apremilast</title>
            <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Elderly: Apremilast</title>
            <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast</title>
          <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2900" spread="28.7"/>
                    <measurement group_id="O2" value="3323" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the effect of age on the PK of apremilast after a single 30 mg dose, a 2-way analysis of variance (ANOVA) model was performed on the log-transformed AUC0-∞. The ANOVA model included age group (elderly and young), sex (male and female), and age group by sex as a fixed effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>113</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.1</ci_lower_limit>
            <ci_upper_limit>135</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Elderly/Young) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex</title>
        <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Males (Combined)</title>
            <description>Male participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Females (Combined)</title>
            <description>Female participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex</title>
          <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2673" spread="24.8"/>
                    <measurement group_id="O2" value="3499" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the effect of sex on the PK of apremilast after a single 30 mg dose, a 2-way ANOVA model was performed on the log-transformed AUC0-∞. The ANOVA model included age group (elderly and young), sex (male and female), and age group by sex as a fixed effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>131</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>109</ci_lower_limit>
            <ci_upper_limit>157</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Female/Male) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Apremilast</title>
        <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Young: Apremilast</title>
            <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Elderly: Apremilast</title>
            <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Apremilast</title>
          <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302" spread="26.8"/>
                    <measurement group_id="O2" value="321" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the effect of age on the PK of apremilast after a single 30 mg dose, a 2-way analysis of ANOVA model was performed on the log-transformed Cmax. The ANOVA model included age group (elderly and young), sex (male and female), and age group by sex as a fixed effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>106</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.5</ci_lower_limit>
            <ci_upper_limit>123</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Elderly/Young) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration of Apremilast by Sex</title>
        <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Males (Combined)</title>
            <description>Male participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Females (Combined)</title>
            <description>Female participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration of Apremilast by Sex</title>
          <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299" spread="16.6"/>
                    <measurement group_id="O2" value="322" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the effect of sex on the PK of apremilast after a single 30 mg dose, a 2-way ANOVA model was performed on the log-transformed Cmax. The ANOVA model included age group (elderly and young), sex (male and female), and age group by sex as a fixed effect.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>108</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.3</ci_lower_limit>
            <ci_upper_limit>126</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Female/Male) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</title>
        <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Young: Apremilast</title>
            <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Elderly: Apremilast</title>
            <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</title>
          <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="0.5" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.50" lower_limit="1.0" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax was analyzed by nonparametric methods. The median difference and 90% CI of the median difference were calculated from the Hodges-Lehrmann estimate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>Wilcoxon rank-sum test</method>
            <param_type>Median Difference</param_type>
            <param_value>0.500</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
            <estimate_desc>Median difference (Elderly - Young) calculated from the Hodges-Lehmann estimate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex</title>
        <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Males (Combined)</title>
            <description>Male participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Females (Combined)</title>
            <description>Female participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex</title>
          <description>The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.</description>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.5" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.75" lower_limit="1.0" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax was analyzed by nonparametric methods. The median difference and 90% CI of the median difference were calculated from the Hodges-Lehrmann estimate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.169</p_value>
            <method>Wilcoxon rank-sum test</method>
            <param_type>Median Difference</param_type>
            <param_value>0.500</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
            <estimate_desc>Median difference (Female - Male) and 90% CI of the difference calculated from the Hodges-Lehmann estimate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)</title>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Young: Apremilast</title>
            <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Elderly: Apremilast</title>
            <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)</title>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41" spread="2.65"/>
                    <measurement group_id="O2" value="9.15" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex</title>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Males (Combined)</title>
            <description>Male participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Females (Combined)</title>
            <description>Female participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex</title>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.06" spread="1.72"/>
                    <measurement group_id="O2" value="10.3" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast</title>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Young: Apremilast</title>
            <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Elderly: Apremilast</title>
            <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast</title>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="28.7"/>
                    <measurement group_id="O2" value="9.03" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex</title>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Males (Combined)</title>
            <description>Male participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Females (Combined)</title>
            <description>Female participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex</title>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="24.8"/>
                    <measurement group_id="O2" value="8.57" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast</title>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Young: Apremilast</title>
            <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Elderly: Apremilast</title>
            <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast</title>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" spread="38.9"/>
                    <measurement group_id="O2" value="115" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex</title>
        <time_frame>Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.</time_frame>
        <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Males (Combined)</title>
            <description>Male participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Females (Combined)</title>
            <description>Female participants received a single oral dose of 30 mg apremilast on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex</title>
          <population>The PK population included all participants who received apremilast and had evaluable PK profiles.</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="30.7"/>
                    <measurement group_id="O2" value="123" spread="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of apremilast up to 11 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Young Males</title>
          <description>Men aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Young Females</title>
          <description>Women aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Young (Total)</title>
          <description>Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Elderly Males</title>
          <description>Men aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Elderly Females</title>
          <description>Women aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Elderly (Total)</title>
          <description>Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Overall Total</title>
          <description>All study participants received a single oral dose of 30 mg apremilast on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

